Press release
Top Factor Driving Gastric Cancer Drugs Market Growth in 2025: Rising Gastric Cancer Cases Fuel Growth In Gastric Cancer Drugs Market
Gastric Cancer Drugs
The rise in obesity and smoking rates has led to an increased prevalence of gastric cancer. Factors like tobacco use and poor dietary habits have been linked to a higher risk of developing this disease. As per data from the Government Digital Service in the UK, it was projected in May 2023 that there was a rise in obesity among individuals aged 18 and above in England, with 25.9% reported to be obese in 2022-2023, marking an increase from the previous figure of 25.2%. This growing incidence of gastric cancer is expected to have a positive impact on the gastric cancer drugs market's growth.
Get Your Gastric Cancer Drugs Market Report Here:
https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report
How will the growth rate of the gastric cancer drugs market shape industry trends by 2034?
Over the last few years, there has been a significant escalation in the size of the gastric cancer drugs market. It is projected to expand from $4.43 billion in 2024 to around $5.01 billion in 2025, marking a Compound Annual Growth Rate (CAGR) of 12.9%. The upward movement during the historical period is largely because of factors like growth in pharmaceutical research and development spending, higher healthcare outlays, robust economic advancement in up-and-coming markets, and a swift increase in the elderly demographic.
The market for drugs treating gastric cancer is predicted to experience significant growth in the upcoming years, with a prospective value of $7.6 billion by 2029, marking a compound annual growth rate of 11.0%. Several factors are set to contribute to this expansion in the forecasted period, including the rising incidence of gastric cancer, a robust drug pipeline, an uptick in acquisitions and partnerships, growing healthcare spending, an aging population, and altered FDA guidelines promoting the development of biologic drugs. The forecasted period is also expected to witness several prevailing trends, such as strategic collaborations and agreements to expand product arrays, partnerships with other enterprises or government entities, an increase in pipeline research for the development of gastric cancer drugs, investment in AI solutions to decrease R&D expenses, and the creation of next-generation biologics and incorporation of CRISPR-cas9 technology in drug development.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp
What trends are poised to drive the future success of the gastric cancer drugs market?
Numerous firms in the gastric cancer drugs market are pioneering sophisticated products like anti-PD-1 therapies to boost treatment effectiveness and elevate patient results. Anti-PD-1 therapy is a category of immunotherapy that takes aim at the programmed cell death protein 1 (PD-1) receptor present on immune cells. For example, in November 2023, the US-based pharmaceutical corporation Merck & Co., Inc. secured approval from the Food and Drug Administration (FDA), a US federal agency dedicated to public health protection, for KEYTRUDA (pembrolizumab). This therapy, used to treat gastric cancer, is intended as a first-line treatment for patients suffering from locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. Specifically, it is meant to be used in conjunction with trastuzumab and fluoropyrimidine- and platinum-contained chemotherapy. The approval was expedited based on the tumor's response rate and the duration of the said response.
Which primary segments of the gastric cancer drugs market are driving growth and industry transformations?
The gastric cancer drugs market covered in this report is segmented -
1) By Type: Imatinib, Trastuzumab, Other Types
2) By Route of Administration: Oral, Parenteral
3) By End User: Hospitals, Clinics, Cancer Speciality Centers
Subsegments:
1) By Imatinib: Oral Formulations, Injectable Formulations, Combination Therapies
2) By Trastuzumab: Monotherapy, Combination Therapy With Chemotherapy, Biosimilars Of Trastuzumab
3) By Other Types: Chemotherapy Agents, Targeted Therapy Agents, Immunotherapy Agents, Supportive Care Medications
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2603
Which geographical regions are pioneering growth in the gastric cancer drugs market?
North America was the largest region in the gastric cancer drugs market in 2024. Middle East is expected to be the largest growing region in the global gastric cancer drugs market share during the forecast period. The regions covered in the gastric cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Who are the influential players reshaping the gastric cancer drugs market landscape?
Major companies operating in the gastric cancer drugs market include F. Hoffmann-La Roche, Eli Lilly and Company, Otsuka Pharmaceutical, Jiangsu HengRui Medicine, Biocon, Sanofi, PV Pharma Healthcare (India), Roche India, Novartis Oncology, Arlak Biotech (India), Healthkind labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd, Apikos Pharma, Kolaz biotech., CStone Pharma (China), CARsgen Therapeutics (China), JW Therapeutics (China), BeiGene(China), Takeda Pharmaceuticals (Japan), Astellas Pharma Inc (Japan), Daiichi Pharmaceutical and Sankyo (Japan), AQVIDA GmbH, AstraZeneca plc, GlaxoSmithKline plc, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celltrion Inc., Imugene Limited, Merck & Co. Inc., Pfizer Inc., Sandoz AG (A Novartis Division), Eurofarma Laboratórios S.A., TUTEUR ArgentinaPierre Fabre Group, Celnova Pharma, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO), Gulf Pharmaceutical Industries (Julphar), Abbott Laboratories, Mylan Laboratories, Gilead Sciences, BMS, Ascedis Health
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=2603&type=smp
What Is Covered In The Gastric Cancer Drugs Global Market Report?
• Market Size Forecast: Examine the gastric cancer drugs market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the gastric cancer drugs market for a structured understanding.
• Key Players Overview: Analyze major players in the gastric cancer drugs market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the gastric cancer drugs market.
• Segment Contributions: Evaluate how different segments drive overall growth in the gastric cancer drugs market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the gastric cancer drugs market.
• Industry Challenges: Identify potential risks and obstacles affecting the gastric cancer drugs market.
• Competitive Landscape: Review strategic developments in the gastric cancer drugs market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Top Factor Driving Gastric Cancer Drugs Market Growth in 2025: Rising Gastric Cancer Cases Fuel Growth In Gastric Cancer Drugs Market here
News-ID: 3902732 • Views: …
More Releases from The Business Research Company
Tacrolimus Market Poised to Hit $8.68 Billion by 2029 with Accelerating Growth T …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Tacrolimus Market Size Growth Forecast: What to Expect by 2025?
The market size of tacrolimus has seen robust growth over the past few years. It is projected to increase from $6.59 billion in 2024 to $6.97 billion in 2025, with a compound annual growth rate (CAGR) of 5.7%. The…
Future of the Research-Grade Proteins Market: Strategic Analysis and Forecast to …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Research-Grade Proteins Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Recent years have seen a significant expansion in the market size for research-grade proteins. The market, which was valued at $1.11 billion in 2024, is projected to rise to $1.33 billion in 2025, marking a…
Key Trends Influencing the Growth of the Peptide Based Metabolic Disorders Thera …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Peptide Based Metabolic Disorders Therapeutics Market Through 2025?
The market size for therapeutics centered around peptide-based metabolic disorders has visibly expanded in the last few years. It is projected to escalate from $29.89 billion in 2024 to $34.1 billion in 2025, reflecting…
Oral Transmucosal Drugs: Core Growth Enabler in the Parkinson's Disease Driving …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Oral Transmucosal Drugs Industry Market Size Be by 2025?
Significant growth has been observed in recent years in the market for oral transmucosal drugs. The market, valued at $39.7 billion in 2024, is predicted to expand to $43.21 billion in 2025, with a compound annual growth…
More Releases for Pharma
Miglitol Market Size, Share and Forecast By Key Players-Weiao Pharma, Zhejiang M …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Miglitol market is anticipated to grow at a compound annual growth rate (CAGR) of 11.49% between 2024 and 2031. The market is expected to grow to USD 22.32 Billion by 2024. The valuation is expected to reach USD 47.79 Billion by 2031.
The Miglitol market is experiencing significant growth due to the rising prevalence of diabetes and the increasing awareness of the…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasing…
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. As…
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the…
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, …
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoring…
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 …
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Global Roxatidine Market overview:
Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the…
